Lifecore Biomedical Amends Manufacturing Agreement with Alcon, Extends Term

What Happened
Lifecore Biomedical, Inc. reported on September 29, 2026 (via an 8-K) that its subsidiary Lifecore Biomedical, LLC entered into Amendment No. 3 to its Amended and Restated Contract Manufacturing Agreement with Alcon Research, LLC. The Third Amendment was signed September 24, 2026 and is effective November 1, 2026. It extends the agreement’s term and updates purchase and supply commitments between the parties.

Key Details

• The Contract Manufacturing Agreement term is extended from December 31, 2031 to an Initial Term ending December 31, 2034, then will automatically renew for successive 24‑month periods unless proper notice is given.
• An exhibit to the agreement was amended to establish Alcon’s minimum purchase obligations through 2034 and certain supply obligations of Lifecore.
• Beginning November 1, 2026, Lifecore agreed not to enter into new development, supply or manufacturing agreements for certain products that directly compete with specified Alcon products; this restriction does not affect agreements in existence before that date or renewals on substantially similar or better terms for Lifecore.
• The Third Amendment will be filed as an exhibit to Lifecore’s Form 10‑Q for the quarter ended September 30, 2026.

Why It Matters
This amendment formalizes a longer commercial relationship with Alcon through at least 2034 and sets minimum purchase and supply expectations, which could provide more predictable manufacturing volumes and revenue for Lifecore. The new limitation on entering certain competing product agreements narrows Lifecore’s ability to take on new work that conflicts with Alcon’s products, which investors should weigh when assessing future business development opportunities.